← SynDRA
UMBRALISIB
SynDRA canonical compound SYN0038660 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Approval status | Approved · OTC |
|---|
| Primary target(s) | PIK3CD |
|---|
| Mechanism of action | PI3K inhibitor |
|---|
All known targets
- CSNK1E
- PIK3CD
- ABL1
- PIK3CA
- PIK3CB
- PIK3CG
Mechanisms of action (all sources)
- PIK3CD INHIBITOR
- PI3-kinase p110-delta subunit inhibitor
- CSNK1E INHIBITOR
- Casein kinase I epsilon inhibitor
- ABL1 INHIBITOR
- Tyrosine-protein kinase ABL inhibitor
- PI3K inhibitor
- casein kinase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SYK
- ABL2
- PDGFRA
- PIM3
- PIM2
- PIM1
- PHKG2
- PHKG1
- PEAK1
- PDPK1
- PDGFRB
- PBK
- PKN2
- PASK
- PAK6
- PAK5
- PAK4
- PAK3
- PAK2
- PAK1
- PKN1
- PKN3
- OGG1
- PRKCE
- PRKD3
- PRKD2
- PRKD1
- PRKCZ
- PRKCQ
- PRKCI
- PRKCH
- PRKCG
- PRKCD
- PLK1
- PRKCB
- PRKCA
- PRKACG
- PRKACB
- PNCK
- PLK4
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Kinase Inhibitors
- Kinase Inhibitor
- Phosphoinositide-3 Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- UKONIQ
- umbralisib tosylate
- ukoniq
- TGR-1202
- RP-5264
- RP5264
- TGR-1202 FREE BASE
- TGR-1202 base
- RP 5264
- TGR-1202 free base
- TGR1202
- umbralisibum
- RefChem:58319
- DTXCID501767488
- Umbralisib [USAN]
- MFCD28386165
- UNII-38073MQB2A
- TGR 1202 [WHO-DD]
- C31H24F3N5O3
- UMBRALISIB [INN]
- Umbralisib (USAN/INN)
- umbralisib (TGR-1202)
- UMBRALISIB [WHO-DD]
- GTPL8916
- orb1302401
- SCHEMBL15557416
- SCHEMBL29354189
- SCHEMBL29358460
- SCHEMBL29454795
- IUVCFHHAEHNCFT-INIZCTEOSA-N
- BDBM184556
- GLXC-10704
- EX-A1645
- NSC793696
- NSC800405
- s8194
- AKOS025396183
- example A1 [US2014011819]
Look up UMBRALISIB in the interactive SynDRA portal →